ICUSeaStar Medical Holding Corp

Nasdaq N/A


$ 4.89 $ -0.28 (-5.32 %)    

Friday, 13-Sep-2024 15:59:46 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 4.895
$ 4.88 x 100
-- x --
-- - --
$ 3.25 - $ 42.92
71,373
na
20.41M
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 04-16-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-16-2022 06-30-2022 10-Q
10 05-19-2022 03-31-2022 10-Q
11 04-06-2022 12-31-2021 10-K
12 11-17-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-24-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 seastar-medical-holding-q2-2024-gaap-eps-103-beats-141-estimate

SeaStar Medical Holding (NASDAQ:ICU) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate o...

 why-nuwellis-stock-is-climbing
Why Nuwellis Stock Is Climbing
07/29/2024 17:13:50

Nuwellis shares are trading higher Monday after the company announced Friday that the first pediatric patient has been treated ...

Core News & Articles

QUELIMMUNE, Manufactured For SeaStar Medical And Licensed By Nuwellis, Targets Pediatric AKI Patients With Sepsis Requiring Kid...

 seastar-medical-announces-first-pediatric-patient-treated-in-a-commercial-setting-with-its-fda-approved-quelimmune-therapeutic-device

SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar Medical) reports treatment of the first patient in a commercial setti...

Core News & Articles

Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid...

 seastar-medical-announces-receipt-of-a-category-b-coverage-letter-from-the-us-cms-for-the-neutralize-aki-pivotal-trial-evaluating-the-cos-selective-cytopheretic-device-in-adults-with-acute-kidney-injury

Reimbursement expected to accelerate medical site activations and cover a portion of the Company's NEUTRALIZE-AKI trial cos...

 why-seastar-medical-stock-is-trading-higher-wednesday

SeaStar announced that the FDA has agreed to the final labeling for QUELIMMUNE, a novel treatment for children with acute kidne...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION